News


Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017

AroCell AB (publ) announces today that the abstract entitled: “Quantification of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentrations (sTK1)”, by B Tribukait et al was published today by the ESMO Asia congress organizers

https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/session/calendar?q=Tribukait

The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery. Serum TK1 levels correlated to clinical/radiologically determined tumor response after cycles 2, 4 and 6, as well as pathologically determined response and disease-free survival. (To read the full abstract, please visit the ESMO Asia 2017 website.)

The investigators found that serum TK1 levels measured at the base-line and after completion of four cycles of treatment correlated significantly with clinical/radiological response during treatment and tumor-status at surgery. “This study shows that the reduction of tumor size and response to therapy can be assessed with our TK 210 ELISA” says Jan Stålemark, AroCell CEO. “Our product TK 210 ELISA was used in this study to investigate whether or not TK1 concentration can be a significant predictor of treatment response during chemotherapy of breast cancer. This is another study showing that serum TK1 measured with TK 210 ELISA is a promising biomarker for monitoring treatment response and possibly as a tool in clinical drug development. It gives a prompt signal on whether the new therapy works or not”.

 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 09:30 CET on 08 November 2017.

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell’s Certified Adviser.

AroCell press release Final Nov 8 2017

AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.

“We very much look forward to this new collaboration with the England based Pathway Diagnostics for the distribution of our TK 210 ELISA test”, states Jan Stålemark, AroCell CEO. “Pathway Diagnostics Ltd is a leading supplier of specialist clinical and research diagnostics in the UK and was established in 1998 to provide high quality in-vitro diagnostic products and instrumentation to clinical, research and industrial laboratories mainly in the UK and Ireland. Pathway Diagnostics are highly focused on the needs of their customers and in providing the highest quality products and service and therefore we consider them as a perfect match for our TK 210 ELISA test.”

The TK 210 ELISA test will be commercially available immediately through Pathway Diagnostics in the UK and Irish market.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:50 CET on 13 October 2017.

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provide valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during  monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell’s Certified Adviser.

Press Release Distribution UK20171011_final

AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017

AroCell AB (publ) announces today that a research poster submitted by Jagarlamudi K.K. et al. entitled ”AroCell TK 210 ELISA may complement pro PSA and the prostate health index in differentiating non-cancerous from cancerous conditions in prostate disease” has been accepted by the UK NICR for presentation at its annual meeting in November 5-8, 2017.

Thymidine kinase 1 (TK1) is a well-known cell proliferation biomarker. The purpose of this study was to compare the TK1 assayed with the AroCell TK 210 ELISA kit with PSA, free PSA, pro PSA and PHI (Prostate Health Index) in men with non-cancerous prostate conditions and patients with confirmed prostate cancer.

Serum samples with known PSA values from subjects investigated for prostate cancer were collected by the University Medical Centre, Ljubljana. Overall, AroCell TK 210 ELISA results showed significant correlation with PHI (r = 032, P = 0.0017) and pro PSA
(r = 021 P = 0.044) but not with free PSA or PSA. Combining the TK 210 value with the PHI or pro PSA value increased the diagnostic accuracy for prostate cancer compared with either individually.

CEO Jan Stålemark states “We are delighted that this preliminary study demonstrated that serum TK1 assayed with AroCell TK 210 ELISA kit can differentiate between non-cancerous conditions and prostate cancer patients with a similar accuracy to that of pro PSA or PHI. Further clinical studies will establish the capacity of AroCell TK 210 ELISA to complement pro PSA and PHI in distinguishing between non-cancerous and prostate cancer, potentially providing another tool in prostate cancer management”.

This data was previously presented at the American Academy for Cancer Research Annual Meeting April 2017.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

 

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11.00 CET on 26 September 2017.

 

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell’s Certified Adviser.

AroCell press release 26 Sept 2017

AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium

AroCell AB (publ) announces today that an abstract submitted Kiran Kumar Jagarlamudi et al entitled “The AroCell TK 210 ELISA provides new information concerning the mechanism of anti-cancer drugs by determining the TK1 protein levels in cultured cells in vitro” was accepted by the NCRI for presentation at their annual meeting in Liverpool, November 5-8, 2017.

The purpose of this study was to evaluate the capacity of TK 210 ELISA to measure TK1 levels in tumor cell culture models, using CEM lymphoblastic cells and Doxorubicin, which is an effective anti-neoplastic drug for both hematological and solid malignancies, and a commonly used chemotherapy drug. The conclusion in the study is that use of AroCell TK 210 ELISA provides opportunities for in-vitro studies of old and new anti-cancer drugs, targeting cell proliferation, which may assist in the development of new therapeutic agents.

“We are delighted over the results in this study and it is another piece of evidence that TK 210 ELISA will have a very broad applicability also in early stage drug development” states Jan Stålemark, CEO. “Controlling and/or inhibiting cell proliferation is an important parameter in early drug development and thus in the selection of drug candidates for cancer therapy. However, there are few cell-proliferation biomarkers which are suitable for large-scale use in in-vitro studies. This present work shows that TK1 levels in-vitro can be used to gain information on the effects of anti-cancer agents with tumor derived model cell lines. Furthermore, measuring the serum TK1 levels in patients with the TK 210 ELISA has been shown to provide clinically valuable information in a range of malignancies. This means that the assay of TK1 with the AroCell TK 210 ELISA test has the potential to enable routine application to drug discovery studies and in clinical trials. This potential is reinforced by another recent abstract on cell culture entitled Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development” says Jan Stålemark.

 

 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

 

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11.30 CET on 22 September 2017.

 

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

AroCell press release Sept 22, 2017

New application for AroCell TK 210 ELISA opens new opportunities for drug development research

AroCell AB (publ) announces today that an abstract submitted by Kiran Kumar Jagarlamudi et al entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development” was accepted by the Purine and Pyrimidine Society for presentation at their annual meeting in Gdansk, Poland, September 20-24, 2017.

The purpose of this study was to evaluate the capacity of AroCell TK 210 ELISA to measure TK1 protein levels in cultured tumor cell lines. The effects of Doxorubicin on TK1 protein levels in extracts and media from CEM lymphoblastic cells as well as MDA-MB breast cancer cell cultures were studied for 24 hours. The results demonstrated that changes in intracellular and extracellular TK1 protein levels at different concentrations of DOX provide information about induction of TK1 in the cells, probably related to DNA damage, as well as release of TK1 protein into the media due to cytotoxicity.

“The results are very promising and demonstrate that AroCell TK 210 ELISA can be used to determine TK1 as a biomarker in in-vitro cell culture studies with drugs targeting cell proliferation and DNA repair. This means that our TK 210 ELISA test also has the potential to enable routine application in drug development studies” says Jan Stålemark AroCell CEO.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 14:15 CET on 18 September 2017.

 About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

AroCell press release Sept 18, 2017

AroCell AB Interim Report, Q2 2017

AroCell AB (publ)
Reporting period 1 April – 30 June 2017

  • Net sales were 237 (0) KSEK
  • Losses after financial items were – 3,606 (- 1,962) KSEK
  • Earnings per share were – 0.27 (- 0.17) SEK
  • Cash flow from operating activities was – 3,163 (- 1,229) KSEK
  • Cash flow from investing activities was – 318 (- 1,800) KSEK

 

Interim report, 1 January – 30 June 2017

  • Net sales were 293 (0) KSEK
  • Losses after financial items were – 7,831 (- 4,804) KSEK
  • Earnings per share were – 0.27 (- 0.17) SEK

Revenues and expenses April – June 2017 (2016) KSEK

Sales for the period were 237 (0). Expenses were 3,771 (1,962). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 3,762. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -3,531 (-3,029). Cash at the end of the period was 24,423.

Revenues and expenses January – June 2017 (2016) KSEK

Sales for the period were 293 (0). Expenses were 8,052 (4,804). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 9,824. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -8,429 (-7,521). Cash at the end of the period was 24,423.

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through Jan Stålemark, at 08:15 CET on 24 August 2017.

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser. For the full Q2 Interim Report, please refer to the enclosed pdf file Interim report, Q2 2017

Beslut vid årsstämman i AroCell AB (publ) 2017

Beslut vid årsstämman i AroCell AB (publ) 2017

Vid dagens årsstämma i AroCell AB (publ) beslutades följande:

Årsstämman fastställde resultaträkningen för 2016 och balansräkningen per den 31 december 2016.

Resultatdisposition
I enlighet med styrelsens förslag beslutade årsstämman att disponera vinstmedlen så att ansamlad förlust om 51 544 162 kronor samt överkursfond om 102 614 663 kronor balanseras i ny räkning.

Årsstämman beviljade styrelsens ledamöter och verkställande direktören ansvarfirhet för räkenskapsåret 2016.

Styrelse
Årsstämman beslutade att antalet styrelseledamöter ska uppgå till sju och inga suppleanter.
Årsstämman beslutade att arvodet till styrelseordförande ska uppgå till 150 000 kronor och 60 000 kronor vardera till övriga ledamöter.
Årsstämman omvalde Staffan Eriksson, Carl Blomqvist och Christine Tadgell samt nyvalde Agneta Franksson, Johan von Heijne, Claes Post samt Gunnar Steineck. Stämman valde Claes Post till ordförande.

Revisor
Till revisorer omvaldes Ernst & Young AB till revisorer med Björn Ohlsson som huvudansvarig revisor. Det beslöts att ersättning till revisorerna utgår enligt godkänd räkning.

Bolagsordning
Årsstämman beslutade att komplettera bolagsordningens verksamhetsparagraf så att det lyder ”Företagets verksamhet består av forskning och utveckling inom cellbiologi och medicin för kommersiella applikationer som cancerdiagnostik, prognos, behandlingsuppföljning och marknadsföring och försäljning av produkter samt därmed förenlig verksamhet.”

Personaloptionsprogram 2017/2020
Årsstämman beslutade att införa ett personaloptionsprogram 2017/2020. Det är angeläget och i alla aktieägares intresse att ledande befattningshavare och övriga nyckelpersoner, vilka bedömts vara viktiga för AroCells vidare utveckling, har ett långsiktigt intresse av en god värdeutveckling på aktien i AroCell AB (publ). Ett personligt långsiktigt ägarengagemang förväntas stimulera ett ökat intresse för verksamheten och resultatutvecklingen i sin helhet samt höja motivationen för de ledande befattningshavarna och övriga nyckelpersoner och resultera i en ökad intressegemenskap med ägarna i AroCell.

Maximalt kan 575 000 aktier nyemitteras vilket medför en utspädning på ca två procent. VD kan tilldelas 30 procent CFO kan tilldelas 15 procent, övriga anställda 15 procent samt 40 procent sparas för nya medarbetare. Tilldelning sker vid tre olika tillfällen och med en tredjedel av maximal tilldelning per gång. Tilldelningen är vederlagsfri. Lösenpriset är 6,76 kronor och personaloptionerna kan utövas för att teckna aktier i bolaget under perioden 1 januari 2018 till 31 december 2020.

För att säkra personaloptionsprogrammet beslöts om en riktad emission av teckningsoptioner till dotterbolag vidare beslutades att överlåtelse av teckningsoptioner eller i aktier i AroCell AB (publ) till anställda för att säkerställa Bolagets åtaganden i anledning av Personaloptionsprogram 2017/2020.

Bemyndigande för styrelsen att emittera aktier, konvertibler eller teckningsoptioner
Årsstämman beslutade bemyndiga styrelsen att besluta om nyemission av aktier eller emission av konvertibler eller teckningsoptioner. Om styrelsen beslutar om emission utan företrädesrätt för aktieägarna så ska skälet vara att kunna bredda ägarkretsen, anskaffa eller möjliggöra anskaffning av rörelsekapital, öka likviditeten i aktien, genomföra företagsförvärv eller anskaffa eller möjliggöra anskaffning av kapital för företagsförvärv. Vid beslut om emissioner utan företrädesrätt för aktieägarna ska teckningskursen vara marknadsmässig vid tidpunkten för emissions-beslutet. Vidare beslutades om ett bemyndigande för verkställande direktören att vidta de formella justeringar i beslut enligt punkten ovan som kan visa sig erforderliga i samband med registrering och verkställande därav.

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Ann Hammarstrand, at 18.30 CET on 18 May 2017.

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

Beslut vid årsstämman i AroCell AB (publ) 2017 (PDF)

AroCell AB (publ) Interim report for period 1 January – 31 March 2017

 

AroCell AB (publ)

Interim report for period 1 January – 31 March 2017

  • Net sales were 56 (0) KSEK
  • Loss after financial items was – 4,225 (- 2,842) KSEK
  • Earnings per share were -0.15 (-0.10) SEK
  • Cash flow from operating activities was -4,898 (-1,272) KSEK
  • Cash flow from investing activities was 0 (-3,220) KSEK

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:25 CET on 11 May 2017.

 About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

 

Significant events during the reporting period

  • A scientific poster showing the correlation between TK 210 ELISA and Prostate Health Index (PHI) was accepted by AARC, American Association of Cancer Research.
  • AroCell participated at the World Biomarker Congress in Manchester, UK in February.
  • A webinar entitled “Improved Monitoring of Tumor Growth with a Novel Serum Proliferation Biomarker” was held on March 23rd, with 135 participants from both industry and academia.

 

Significant events after the reporting period

  • AroCell attended the AACR congress in Washington, DC together with its distribution partner Eagle Biosciences.
  • The Biomarker and World Congress in Philadelphia on May 2-4.

Comments by CEO Jan Stålemark

A key priority for Arocell in 2017 is to ensure that we have a strong strategic framework in place to maintain focus for our activities and drive commercial growth. We have identified key areas where we will focus on moving forward which include elements to support both the commercial and clinical strategies.

Our commercial activities have increased significantly during the last period. We have seen a very positive response to our diverse marketing activities. These activities have generated significant interest in our product, providing plenty of contacts and leads for us to follow up on. We are thereby now able to make advances in commercializing our CE-marked TK 210 ELISA kit into the clinical research market.

The clinical validation is a key focus to ensure customer acceptance for long term growth. We have made good progress in the clinical development plans and expect to be presenting preliminary and interesting results soon. The Swedish Promix multicentre study has been analysed and publication is planned. Both our prospective studies, Sarcoma at Helsinki hospital and Prostate cancer at the South Hospital in Stockholm are on plan and expected to be completed by the end of 2018. We have also completed the analysis of the biobank samples in the U-CAN study in Uppsala. The remaining work is to get the results analysed in correlation to the patient records which will be done by the clinicians at Uppsala Academic Hospital. This is key to our strategy in obtaining clinical acceptance through clinical validation, in order to introduce our product to the global in vitro diagnostic market.

As prostate cancer is a key component in our clinical development program, it is essential to communicate the results to the medical community. A scientific poster was presented at the AARC, American Association of Cancer Research. It shows significant correlation between results by TK 210 ELISA and Prostate Health Index (PHI), a new index to determine patient status for individuals with suspected or confirmed prostate cancer. The study compare AroCell’s TK 210 ELISA test with other commonly used test methods such as PSA, free PSA, pro PSA and PHI in men with pre-cancerous conditions and confirmed prostate cancer indicates that AroCell’s TK 210 ELISA test provides valuable clinical information.

We have the only CE-marked kit on the market that measures concentrations of TK 1 protein in serum from a simple blood test based on the global standardized ELISA format. Our product’s uniqueness has generated interest well above our expectations during meetings with potential customers from the research and medical communities at trade shows and conferences. This will be a strong basis to find new partners and markets in 2017.

With a robust product, commercially available and with an increased customer interest, we are now putting full efforts behind our plans for launching the TK 210 ELISA kit into the clinical research market as well as the ongoing clinical development program.

Jan Stålemark

CEO

 For the full interim report please see the enclosed pdf:
AroCell Q 1 2017 report FINAL

KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)

Aktieägarna i AroCell AB (publ), org. nr. 556596-6107 (“Bolaget”) kallas härmed till årsstämma torsdagen den 18 maj 2017, kl. 15 i lokalen Karin Boye på Virdings allé 32B i Uppsala. Registreringen börjar 14.30 och avbryts när stämman öppnas.

 

 

Aktieägare som önskar delta i årsstämman ska:

  • dels vara införd i eget namn i den av Euroclear Sweden AB förda aktieboken fredagen dn 12 maj 2017, och
  • dels anmäla sitt deltagande så att denna är Bolaget tillhanda senast 16.00 fredagen den 12 maj 2017, under adress AroCell AB (publ), Virdings allé 32B, 754 50 Uppsala alternativt e-mail till bolagsstämma2017@arocell.com.

 

Se bif pressmeddelande i pdf för mera information:

Kallelse till årsstämma 2017 AroCell AB (Publ) final, april 13

 

AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)

AroCell AB (publ) announces today that a research poster submitted by Kiran Kumar J et al entitled ”The AroCell TK 210 ELISA may complement Pro PSA and the Prostate Health Index in differentiating pre-cancerous and cancerous conditions in prostate cancer” was accepted by the AARC for presentation at their annual meeting in April 2017.

The purpose of this study was to compare the AroCell TK 210 ELISA with PSA, free PSA, pro PSA and PHI (prostate health index) in men with pre-cancerous conditions and patients with confirmed prostate cancer.

Serum samples from 94 patients with known PSA values for prostate cancer were collected by the University Medical Centre, Ljubljana. Overall, the AroCell TK 210 ELISA showed significant correlation with PHI (r=032, P=0.0017) and pro PSA (r021 P=0.044) but not with free PSA or PSA.

CEO Jan Stålemark states “We are delighted that this preliminary study demonstrates that serum TK1 assayed with AroCell TK 210 ELISA can differentiate between pre-cancerous conditions and prostate cancer patients with a similar accuracy to that of pro PSA.  Further clinical studies will establish the capacity of AroCell TK 210 ELISA to complement pro PSA and PHI in distinguishing between pre-cancerous and prostate cancer, potentially providing another tool in prostate cancer management”.

 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

 

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 11:45 CET on 24 January 2017.

 

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,600 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

AroCell Press Release Jan 24, 2017